Inventor
SLUSHER BARBARA
US28 patents
Patents
28 patentsUS10954257B2Mar 23, 2021
Prodrugs of glutamine analogs
UNIV JOHNS HOPKINS4 citations83
US10738066B2Aug 11, 2020
Prodrugs of glutamine analogs
UNIV JOHNS HOPKINS5 citations83
US10568868B2Feb 25, 2020
Methods and compositions for treating metabolic reprogramming disorders
UNIV JOHNS HOPKINS8 citations83
US10336778B2Jul 2, 2019
Prodrugs of glutamine analogs
UNIV JOHNS HOPKINS8 citations83
US9988407B2Jun 5, 2018
Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
UNIV JOHNS HOPKINS11 citations82
US10842763B2Nov 24, 2020
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
UNIV JOHNS HOPKINS8 citations79
US11331271B2May 17, 2022
Buccal, sublingual and intranasal delivery of fospropofol
UNIV JOHNS HOPKINS2 citations71
US11325931B2May 10, 2022
Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
UNIV JOHNS HOPKINS2 citations71
US11059775B2Jul 13, 2021
Prodrug compositions and utility of hydroxamate-based GCPII inhibitors
UNIV JOHNS HOPKINS2 citations71
US10849915B2Dec 1, 2020
Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
UNIV JOHNS HOPKINS3 citations71
US10544176B2Jan 28, 2020
Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
UNIV JOHNS HOPKINS2 citations71
US10172873B2Jan 8, 2019
Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
UNIV JOHNS HOPKINS2 citations71
US11110104B2Sep 7, 2021
Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
UNIV JOHNS HOPKINS2 citations62
US11932664B2Mar 19, 2024
Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
UNIV JOHNS HOPKINS0 citations61
US11926640B2Mar 12, 2024
Prodrugs of glutamine analogs
UNIV JOHNS HOPKINS0 citations61
US11866394B2Jan 9, 2024
Prodrugs of hydroxamate-based GCPII inhibitors
UNIV JOHNS HOPKINS0 citations60
US12492160B2Dec 9, 2025
Prodrugs of itaconate and methyl itaconate
UNIV JOHNS HOPKINS0 citations59
US11759444B2Sep 19, 2023
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
UNIV JOHNS HOPKINS0 citations59
US12527758B2Jan 20, 2026
Use of itaconate and its derivatives/analogues to induce hair growth
UNIV JOHNS HOPKINS0 citations58
US12496284B2Dec 16, 2025
Use of itaconate and its derivatives/analogues to induce hair growth
UNIV JOHNS HOPKINS0 citations58
US11766423B2Sep 26, 2023
2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases
UNIV JOHNS HOPKINS0 citations57
US11185534B2Nov 30, 2021
Prodrugs of glutamine analogs
UNIV JOHNS HOPKINS1 citations55
US11712435B2Aug 1, 2023
Mebendazole prodrugs with enhanced solubility and oral bioavailability
UNIV JOHNS HOPKINS0 citations48
US11759466B2Sep 19, 2023
Inhibition of nSMase for the treatment of human immunodeficiency virus infection
UNIV JOHNS HOPKINS0 citations47
US12195419B2Jan 14, 2025
Glutamine antagonists and uses thereof
UNIV JOHNS HOPKINS0 citations46
US12508271B2Dec 30, 2025
Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy
UNIV JOHNS HOPKINS0 citations44
US12195450B2Jan 14, 2025
Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors
UNIV JOHNS HOPKINS0 citations43
US11427590B2Aug 30, 2022
Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
UNIV JOHNS HOPKINS0 citations41